Good morning, everyone, and how are you today? Yet another busy start here on the Pharmalot corporate campus, where the short people are being hustled off to their various schoolhouses. Perhaps this is somehow fodder for a reality show. In any event, we are recuperating by brewing that mandatory cup of stimulation and hope that you will join us. After all, there is much to do today. Documents must be read, phone calls must be made. Meetings must be arranged. Meanwhile, here are some tidbits to get you started. Have a great one...
FDA Investigates Death Of Novartis Gilenya Patient (Reuters)
Glaxo Sells OTC Brands To Prestige For $660M (Bloomberg News)
AstraZeneca Suffers Pipeline Setbacks And Takes $380M Charge (Bloomberg News)
FDA Adds New Heart Warning To Sanofi's Multaq (USA Today)
Plan B Denial Could Still Be Challenged As Part Of Ongoing Lawsuit (Reuters)
Sanofi Says Aubagio MS Pill Failed To Beat Rebif In Study (Bloomberg News)
EU Widens Approval For Bayer's Xarelto (Dow Jones)
Brand-Name Lipitor Sales Have Fallen By Half (Associated Press)
SE Asia May Be Source Of Fake Anti-Malarials (InPharma Technologist)
Glaxo Gets R&D Grant From Scotland (The Courier)
EDITOR'S NOTE: Please check this post for updates throughout the morning